SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : wla(warner lambert)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Anthony Wong who wrote (821)6/14/1999 5:02:00 PM
From: John Romeo  Read Replies (2) of 942
 
As a new WLA stockholder and a prior Agouron holder, I thought it might be of interest that CNBC ran a piece on "Agouron's" investigational drug for treating common cold, today. Interesting piece. Probably will rerun parts later in day. Overall positive though we are quite aways from submitting NDA.
With all this negative drug sector action has anything held up well?
I was wondering if any posters have considered the 30 odd million new shares issued by WLA overhanging the stock price.Could current price decline be exacerbated by sellers of these new shares?
Any idea when it will end or what needs to happen for this sector to wake up the street.I see and read 30% stock growth this year on WLA from the Company.Will all we see is multiple contraction as our reward?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News